TABLE 3.

Cross-neutralizing activity against heterologous virus, determined by using plasma from antiretroviral-untreated subjects^a

Source of virus	Neutralizing antibody titer from plasma fromb:
	Virologic controller patient			Virologic noncontroller patient
	1504	1508	1516c	1002	1006	1008	1017	1048	1512	1515	3018
Patient groups and ID no.
Controllers
1504	72	82	45	196*	375*	264*	117*	212*	397*	57	101
1508	88*	83	83*	118*	130*	118*	107*	105*	498*	33	103
Noncontrollers
1002	51	67	37	94*	118*	37	51	80*	211*	46
1006	57	99	71*	158*	57	177*	100*	143*	251*	30	50
1008	123*	100	64*	117*	395*	52	68*	114*	192*	33	92
1017	244*	175*	64*	388*	137*	175*	105*	1,119*	175*	425*	114
1048	93*	92	35	131*	350*	64*	95*	102*	573*	50	86
1512	57	56	32	114*	49	55	42	97*	140	33	77
1515	91*	249*	69*	367*	122*	89*	57	310*	615*	41	139
3018	103*	140	81*	249*	266*	187*	153*	198*	1,272*	77*	107
PCAT
2004	39	89	47	56	47	48	48	79*	1,195*	37	81
3002	61	82	58	98*	165*	75*	40	152*	245*	38	78
3037	129*	156	95*	418*	820*	154*	176*	373*	864*	118*	81
3039	56	54	26	229*	153*	55	41	83*	144	43	95
Virus and lab strains
JR-CSF	102	116	75	390	546	182	117	613	314	42	108
NL4-3	4,713	1,720	906	1,891	2,058	639	3,702	5,043	1,950	1,366	781
aMLV	24	58	20	31	26	20	20	22	50	20	65

^aNeutralizing HIV antibody titers were measured in plasma derived from chronically infected, antiretroviral drug-untreated subjects meeting our study definition of virologic controllers or noncontrollers (patient identification [ID] numbers are given). Neutralization titers were measured against a panel of heterologous primary viruses representing all three subject groups (virologic controllers, virologic noncontrollers, and PCAT).

^bSee footnote b of Table 2 for explanations of neutralizing antibody titer, asterisks, and boldface type.

^cVirus could not be amplified for subject 1516.